<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049994</url>
  </required_header>
  <id_info>
    <org_study_id>2018-22</org_study_id>
    <nct_id>NCT04049994</nct_id>
  </id_info>
  <brief_title>Immunomodulation Therapy for Urinary Tract Infections</brief_title>
  <acronym>UROVAXOM-P</acronym>
  <official_title>Immunomodulation Therapy for Primary Prevention of Urinary Tract Infections in Patients With Spinal Cord Injury During First Rehabilitation: a Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Spinal Cord Injury Cohort Study (SwiSCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Paraplegic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infections (UTI) represent one of the most common morbidities in individuals
      with spinal cord injury (SCI) and reason for re-hospitalization. The consequences of
      recurrent UTI are a decrease in quality of life and considerable health costs.
      Immunomodulation therapy with UroVaxom is a very promising method for the prevention of UTI,
      however data in individuals with SCI are very limited. The primary objective of this pilot
      study is to evaluate the feasibility (recruitment rate, patient attrition, compliance,
      assessment procedures etc.) of a main trial. A secondary objective is to collect data for an
      informed sample size calculation. Furthermore, the clinical and biological changes after
      immunomodulation therapy will be investigated.

      This is a randomized, placebo-controlled, mono-centric pilot study investigating the
      feasibility of a main trial regarding the effectiveness of immunomodulation with UroVaxom in
      the prevention of UTI and the effect on the immune system in individuals with acute SCI
      during primary rehabilitation. There will be two parallel groups of 12 participants each.
      Group allocation will be based on a block-randomization stratified according to sex. Study
      participants and outcome assessors will be blinded to the group allocation. The nursing staff
      will be unblinded and will administer the treatment and the placebo. Study participants will
      either receive Uro-Vaxom (one tablet / day) or an off-the-shelf placebo for 90 days. After
      termination of the treatment, the study participants will be followed for 12 months. Blood
      and urine samples will be taken before and 90 days, 6 months and 12 months after treatment
      start.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>randomization rate</measure>
    <time_frame>at study completion, an average of 2 years</time_frame>
    <description>proportion of eligible patients who were enrolled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>positive screening rate</measure>
    <time_frame>at study completion, an average of 2 years</time_frame>
    <description>proportion of eligible patients who were screened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retention rate</measure>
    <time_frame>at study completion, an average of 2 years</time_frame>
    <description>treatment-specific retention rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drop-out rate</measure>
    <time_frame>at study completion, an average of 2 years</time_frame>
    <description>rate of enrolled study participants who do not complete the study protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine culture result</measure>
    <time_frame>during follow-up of 12 months</time_frame>
    <description>bacteria species isolated from urine of study participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in urinary immunoglobulin A levels</measure>
    <time_frame>time 0 and 12 months</time_frame>
    <description>concentration (mg/dl) of immunoglobulin A in the urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>count of urinary tract infection</measure>
    <time_frame>during follow-up of 12 months</time_frame>
    <description>occurrence of a symptomatic urinary tract infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Immunomodulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo tablet once daily for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uro-Vaxom</intervention_name>
    <description>Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.</description>
    <arm_group_label>Immunomodulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute SCI (within 8 weeks after SCI)

          -  onset of SCI within 72h

          -  age from 18 to 70 years

          -  informed consent as documented by signature

        Exclusion Criteria:

          -  known hypersensitivity to investigational product,

          -  other immunomodulation therapy,

          -  other therapies for preventing UTIs (e.g. acidification of urine, cranberries),

          -  immunosuppressant therapy,

          -  oncological condition or therapy,

          -  autoimmune diseases, nephropathy, bladder stones,

          -  women who are pregnant (pregnancy test) or breast feeding,

          -  participation in another study with an investigational drug within the 30 days
             preceding and during the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Pannek, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Paraplegic Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jürgen Pannek, Prof. Dr.</last_name>
    <phone>+41 41 939 5922</phone>
    <email>juergen.pannek@paraplegie.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Wöllner, Dr.</last_name>
    <phone>+41 41 939 5922</phone>
    <email>jens.woellner@paraplegie.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre</name>
      <address>
        <city>Nottwil</city>
        <state>LU</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Pannek, Prof. Dr.</last_name>
      <phone>+41 41 939 5922</phone>
      <email>juergen.pannek@paraplegie.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jens Wöllner, Dr.</last_name>
      <phone>+41 41 939 5922</phone>
      <email>jens.woellner@paraplegie.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jivko Stoyanov, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Krebs, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>neurogenic lower urinary tract dysfunction</keyword>
  <keyword>urinary tract infection</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>immunomodulation</keyword>
  <keyword>immunostimulation</keyword>
  <keyword>E. coli</keyword>
  <keyword>Uro-Vaxom</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

